[VIRTUAL] Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy

[VIRTUAL] Results of a phase II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin (BCG) VPM1002BC in patients with BCG failure - SAKK 06/14

[VIRTUAL] A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISE

[VIRTUAL] Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)

[VIRTUAL] KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)

[VIRTUAL] No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study

[VIRTUAL] Safety and efficacy of A1H in patients with non-muscle invasive bladder cancer awaiting transurethral surgery: A randomized placebo controlled phase I/II study

[VIRTUAL] Identifying immune-related biomarkers to predict clinical outcomes of neoadjuvant immuno-chemotherapy (nivolumab, gemcitabine and cisplatin) in muscle-invasive bladder cancer (NCT03294304)

[VIRTUAL] KEYNOTE-365 cohort c updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)

[VIRTUAL] 5 year progression results from a phase-3 prospective randomized trial of vascular-targeted photo-therapy versus active surveillance for low-risk prostate cancer

[VIRTUAL] Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy, subgroup analysis of EQUINOXE study

[VIRTUAL] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with refractory/metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study

[VIRTUAL] Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

[VIRTUAL] Pembrolizumab (pembro) for docetaxel-pretreated metastatic Castration-Resistant Prostate Cancer (mCRPC): Update on KEYNOTE-199, cohorts 1-3

[VIRTUAL] Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)